Capan-1细胞

【Capan-1】Capan-1细胞/Capan-1细胞/Capan-1人胰腺癌细胞Cell line name Capan-1

Synonyms CaPan-1; CAPAN-1; Capan 1; CAPAN 1; Capan1; CAPAN1

Accession CVCL_0237

Resource Identification Initiative To cite this cell line use: Capan-1 (RRID:CVCL_0237)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: KuDOS 95 cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: NCI RAS program mutant KRAS cell line panel.

Part of: TCGA-110-CL cell line panel.

From: Memorial Sloan Kettering Cancer Center; New York; USA.

Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 923.

Population: Caucasian.

Doubling time: 60-80 hours (CLS=300143); ~50-100 hours (DSMZ=ACC-244); ~49 hours (PBCF).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: CRISPR phenotypic screen.

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Genome sequenced.

Omics: miRNA expression profiling.

Omics: Protein expression by reverse-phase protein arrays.

Omics: Proteome analysis by 2D-DE/MS.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Omics: Transcriptome analysis by serial analysis of gene expression (SAGE).

Misspelling: CANPAN-1; Cosmic=2434105.

Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.

PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720

Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.

Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.

Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

 

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

 

PubMed=1764370; DOI=10.1038/bjc.1991.467; PMCID=PMC1977874

Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C., Kloppel G., Theis B., Russell R.C.G., Neoptolemos J., Williamson R.C.N., Lane D.P., Lemoine N.R.

Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.

Br. J. Cancer 64:1076-1082(1991)

 

PubMed=8426738

Kalthoff H., Schmiegel W.H., Roeder C., Kasche D., Schmidt A., Lauer G., Thiele H.-G., Honold G., Pantel K., Riethmuller G., Scherer E., Maurer J., Maacke H., Deppert W.

p53 and K-RAS alterations in pancreatic epithelial cell lesions.

Oncogene 8:289-298(1993)

 

PubMed=8026879; DOI=10.1002/ijc.2910580207

Berrozpe G., Schaeffer J., Peinado M.A., Real F.X., Perucho M.

Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer.

Int. J. Cancer 58:185-191(1994)

 

PubMed=8286197; DOI=10.1038/bjc.1994.24; PMCID=PMC1968784

Lohr J.-M., Trautmann B., Gottler M., Peters S., Zauner I., Maillet B., Kloppel G.

Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins.

Br. J. Cancer 69:144-151(1994)

 

PubMed=8968085

Goggins M.G., Schutte M., Lu J., Moskaluk C.A., Weinstein C.L., Petersen G.M., Yeo C.J., Jackson C.E., Lynch H.T., Hruban R.H., Kern S.E.

Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.

Cancer Res. 56:5360-5364(1996)

 

PubMed=9331070

Teng D.H.-F., Perry W.L. 3rd, Hogan J.K., Baumgard M.L., Bell R., Berry S., Davis T., Frank D., Frye C., Hattier T., Hu R., Jammulapati S., Janecki T., Leavitt A., Mitchell J.T., Pero R., Sexton D., Schroeder M., Su P.-H., Swedlund B., Kyriakis J.M., Avruch J., Bartel P., Wong A.K.C., Oliphant A., Thomas A., Skolnick M.H., Tavtigian S.V.

Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor.

Cancer Res. 57:4177-4182(1997)

 

PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4; PMCID=PMC1850008

Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A., Meltzer P.S., Ried T.

Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas.

Am. J. Pathol. 154:525-536(1999)

 

PubMed=10408907; DOI=10.1016/S0304-3835(98)00380-2

Bartsch D.K., Barth P., Bastian D., Ramaswamy A., Gerdes B., Chaloupka B., Deiss Y., Simon B., Schudy A.

Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell lines than in primary pancreatic adenocarcinomas.

Cancer Lett. 139:43-49(1999)

 

PubMed=11169957; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1014>3.0.CO;2-U

Wallrapp C., Hahnel S., Boeck W., Soder A., Mincheva A., Lichter P., Leder G., Gansauge F., Sorio C., Scarpa A., Gress T.M.

Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allows differentiation to chronic pancreatitis.

Int. J. Cancer 91:340-344(2001)

 

PubMed=11668190; DOI=10.1177/002215540104901105

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

Immunocytochemical analysis of cell lines derived from solid tumors.

J. Histochem. Cytochem. 49:1369-1378(2001)

 

PubMed=12692724; DOI=10.1007/s00428-003-0784-4

Sipos B., Moser S., Kalthoff H., Torok V., Lohr J.-M., Kloppel G.

A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.

Virchows Arch. 442:444-452(2003)

 

PubMed=14695172

Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V., Shen-Ong G.L.-C., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M.G., Hruban R.H.

Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.

Cancer Res. 63:8614-8622(2003)